EVEROLIMUS MSDS PDF

Acute toxicity: oral toxicity (LD50): > mg/kg (mouse), > mg/kg (rat) – toxicity data from the Abbott Vascular MSDS dated January 16, for Everolimus. SAFETY DATA SHEET. (in accordance with Regulation (EU) /). Everolimus. Version: 1. Revision date: 29/06/ Page 1 of. Material Safety Data Sheet. Section 1 – Product and Company Information. Product Name: Everolimus. Cat. Code: tlrl-eve. Company identification: InvivoGen.

Author: Mojin Gardajin
Country: China
Language: English (Spanish)
Genre: Business
Published (Last): 17 November 2018
Pages: 262
PDF File Size: 14.61 Mb
ePub File Size: 18.69 Mb
ISBN: 611-9-27287-757-2
Downloads: 76132
Price: Free* [*Free Regsitration Required]
Uploader: Samur

Everolimus

Chenodeoxycholic acid The metabolism of Everolimus can be decreased when combined with Chenodeoxycholic acid. Ivabradine The metabolism of Everolimus msdd be decreased when combined with Ivabradine. Daunorubicin The serum concentration of Everolimus can be increased when it is combined with Daunorubicin. Omadacycline The serum concentration of Omadacycline can be increased when it is combined with Everolimus. Apalutamide The everolmus of Everolimus can be everolimys when combined with Apalutamide.

Methohexital The metabolism of Everolimus can be increased when combined with Methohexital. Pentostatin The risk or severity of adverse effects can be increased when Pentostatin is combined with Everolimus.

Debrisoquin The serum concentration of Debrisoquin can be increased when it is combined with Everolimus. Loxapine The serum concentration of Everolimus can be increased when it is combined with Loxapine.

Everolimus CAS#:

Clorazepate The metabolism of Everolimus can be decreased when combined with Clorazepate. Brodalumab The risk or severity of adverse effects can be increased when Everolimus is combined with Brodalumab. Hydroxychloroquine The serum concentration of Everolimus can be increased when it is combined with Hydroxychloroquine.

  BOBBOFITOS EBOOK PDF

Lanatoside C The serum concentration of Lanatoside C can be increased when it is combined with Everolimus. Use appropriate procedures to prevent opportunities for direct contact with the skin or eyes and to prevent inhalation.

Everolimus – DrugBank

Cloricromen The risk or severity of bleeding can be increased when Cloricromen is combined with Everolimus. Amediplase The risk or severity of bleeding can be increased when Amediplase is combined with Everolimus. Coltuximab ravtansine The metabolism of Everolimus can be decreased when combined with Coltuximab ravtansine.

Carbinoxamine Everoliums metabolism of Everolimus can be decreased when combined with Carbinoxamine. Certolizumab pegol The risk or severity of adverse effects can be increased when Everolimus is combined with Certolizumab pegol.

Adverse reactions Some serious adverse reactions associated with Everolimus include non-infection pneumonitis, infections, severe hypersensitivity reactions, angioedema with everoilmus use of ACE inhibitors, stomatitis, renal failure, impaired wound healing, metabolic disorders and myelosuppression [10].

Bacillus calmette-guerin substrain connaught live antigen The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Everolimus. Everolimus is indicated for the treatment of numerous diseases and disorders.

  ANGIOFIBROMA JUVENIL PDF

Glecaprevir The serum concentration of Everolimus can be increased when it is combined with Glecaprevir. Clevidipine The metabolism of Everolimus can be increased when combined with Clevidipine. Carmustine The risk or severity of adverse effects can be increased when Carmustine is combined with Everolimus.

Fingolimod The risk or severity of adverse effects everopimus be increased when Everolimus is combined with Fingolimod. Ifosfamide The metabolism of Everolimus can be increased when combined with Ifosfamide.

Everolimus is a derivative of Rapamycin sirolimusand works similarly to Rapamycin as an mTOR mammalian target of rapamycin inhibitor. Nicotinamide The metabolism of Everolimus can be decreased when combined with Nicotinamide.

Mefloquine The serum concentration of Everolimus can be increased when it is combined with Mefloquine. Use adequate general or local exhaust ventilation to keep airborne concentrations below the permissible exposure limits.

Opium The metabolism of Everolimus can be decreased when combined with Opium.

Enalapril The risk or severity of adverse effects can be increased when Everolimus is combined with Msfs. Nadolol The serum concentration of Nadolol can be increased when it is combined with Everolimus.

Asunaprevir The metabolism of Everolimus can be increased when combined with Asunaprevir.